Evidence map›Paper›PMID 27245411›Full record

ArticleInfection and immunity2016

A Mutation in the 16S rRNA Decoding Region Attenuates the Virulence of Mycobacterium tuberculosis.

Shinya Watanabe, Kazunori Matsumura, Hiroki Iwai, Keiji Funatogawa, Yuji Haishima, Chie Fukui, Kayo Okumura, Masako Kato-Miyazawa, Masahito Hashimoto, Kanae Teramoto and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Heterologous Substitution ofAntibiotics (Basel, Switzerland) · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. OvercomingActa pharmaceutica Sinica. B · 2022
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Shinya WatanabeDepartment of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Kazunori MatsumuraDepartment of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Hiroki IwaiDepartment of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Keiji FunatogawaTochigi Prefectural Institute of Public Health and Environmental Science, Tochigi, Japan.
Yuji HaishimaNational Institute of Health Sciences, Tokyo, Japan.
Chie FukuiNational Institute of Health Sciences, Tokyo, Japan.
Kayo OkumuraObihiro University of Agriculture and Veterinary Medicine, Hokkaido, Japan.
Masako Kato-MiyazawaDepartment of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Masahito HashimotoKagoshima University, Kagoshima, Japan.
Kanae TeramotoJEOL Ltd., Tokyo, Japan.
Fumiko KirikaeDepartment of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Tohru Miyoshi-AkiyamaPathogenic Microbe Laboratory, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
Teruo KirikaeDepartment of Infectious Diseases, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan tkirikae@ri.ncgm.go.jp.
National Center for Global Health and Medicine · JPNational Institute of Health Sciences · JPJEOL (Japan) · JPKagoshima University · JPObihiro University of Agriculture and Veterinary Medicine · JPTochigi Prefectural Police · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycobacterium tuberculosis contains a single rRNA operon that encodes targets for antituberculosis agents, including kanamycin. To date, only four mutations in the kanamycin binding sites of 16S rRNA have been reported in kanamycin-resistant clinical isolates. We hypothesized that another mutation(s) in the region may dramatically decrease M. tuberculosis viability and virulence. Here, we describe an rRNA mutation, U1406A, which was generated in vitro and confers resistance to kanamycin while highly attenuating M. tuberculosis virulence. The mutant showed decreased expression of 20% (n = 361) of mycobacterial proteins, including central metabolic enzymes, mycolic acid biosynthesis enzymes, and virulence factors such as antigen 85 complexes and ESAT-6. The mutation also induced three proteins, including KsgA (Rv1010; 16S rRNA adenine dimethyltransferase), which closely bind to the U1406A mutation site on the ribosome; these proteins were associated with ribosome maturation and translation initiation processes. The mutant showed an increase in 17S rRNA (precursor 16S rRNA) and a decrease in the ratio of 30S subunits to the 70S ribosomes, suggesting that the U1406A mutation in 16S rRNA attenuated M. tuberculosis virulence by affecting these processes.

Indexed as

MutationAnimalsAntitubercular AgentsBase SequenceDrug Resistance, BacterialGenetic Complementation TestMiceMicrobial Sensitivity TestsMicrobial ViabilityMycobacterium tuberculosisNucleic Acid ConformationProteomicsRNA, Ribosomal, 16STuberculosisVirulenceVirulence FactorsAntitubercular AgentsRNA, Ribosomal, 16SVirulence Factors

Identifiers

PMID27245411
PMCPMC4962622
OpenAlexW2480486849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.